プレリキサフォル

プレリキサフォル 価格 もっと(13)

メーカー	製品番号	製品説明	CAS番号	包装	価格	更新時間	購入
富士フイルム和光純薬株式会社(wako)	W01MAS097330	1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzene	110078-46-1	250mg	￥121900	2024-03-01	購入
富士フイルム和光純薬株式会社(wako)	W01COBQB-1271	Plerixafor	110078-46-1	100mg	￥57500	2024-03-01	購入
富士フイルム和光純薬株式会社(wako)	W01COBQB-1271	プレリキサフォル Plerixafor	110078-46-1	250mg	￥97500	2024-03-01	購入
富士フイルム和光純薬株式会社(wako)	W01COBQB-1271	Plerixafor	110078-46-1	1g	￥250000	2024-03-01	購入
富士フイルム和光純薬株式会社(wako)	W01COBQB-1271	Plerixafor	110078-46-1	5g	￥796500	2023-06-01	購入

プレリキサフォル 化学特性,用途語,生産方法

外観

白色～ほとんど白色粉末～結晶

効能

抗悪性腫瘍薬, ケモカイン受容体4(CXCR4)拮抗薬

商品名

モゾビル (サノフィ)

説明

Autologous hematopoietic stem cell (HSC) transplantation, a standard treatment for hematological malignancies, such as non-Hodgkin’s lymphoma or multiple myeloma, involves collection of HSCs from the patient, chemo- or radiotherapy of the patient to eliminate malignant cells, and retransplantation of the stored HSCs.
Plerixafor is a potent antagonist of the CXCR4 chemokine receptor and a first-in-class drug for stem cell mobilization. CXCR4 is specific for stromal-derived-factor-1 (SDF-1), a molecule endowed with potent chemotactic activity forlymphocytes. Because the interaction between SDF-1 and CXCR4 plays an important role in holding HSCs in the bone marrow, drugs that block the activity of CXCR4 receptor are capable of mobilizing HSCs into the bloodstream. In vitro, plerixafor potently blocks SDF-1 binding of CXCR4 and inhibits SDF-1-induced calcium flux (IC₅₀ = 0.01-0.13 mg/mL) and chemotaxis (IC₅₀ = 0.13 mg/mL) in several different cell types. Plerixafor, in combination with G-CSF, is specifically indicated to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma.

化学的特性

White Solid

使用

Plerixafor is a hematopoietic stem cell (HSC) mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-α (SDF-1-α). on Dec. 15, 2008, as treatment in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in p atients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).

副作用

The most common adverse reactions (occurring in more than 10% of patients) observed during plerixafor use include diarrhea, nausea, fatigue, injection-site reactions, headache, arthralgia, dizziness, and vomiting.

プレリキサフォル 上流と下流の製品情報

原材料

準備製品

プレリキサフォル 生産企業

名前	電話番号	電子メール	国籍	製品カタログ	優位度
Anhui Ruihan Technology Co., Ltd	+8617756083858	daisy@anhuiruihan.com	China	994	58
Beijing Cooperate Pharmaceutical Co.,Ltd	010-60279497	sales01@cooperate-pharm.com	CHINA	1811	55
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21691	55
Hangzhou FandaChem Co.,Ltd.	008657128800458; +8615858145714	fandachem@gmail.com	China	9348	55
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32480	60
career henan chemical co	+86-0371-86658258	sales@coreychem.com	China	29914	58
Biochempartner	0086-13720134139	candy@biochempartner.com	CHINA	967	58
Hubei Jusheng Technology Co.,Ltd.	18871490254	linda@hubeijusheng.com	CHINA	28180	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58
Beijing Yibai Biotechnology Co., Ltd	0086-182-6772-3597	sales04@yibaibiotech.com	CHINA	419	58

110078-46-1(プレリキサフォル)キーワード:

---

• 110078-46-1
• 1,1'-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane
• 1,4,8,11-Tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-
• Mozobil
• Sdz sid 791
• Unii-S915p5499n
• 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
• Plerixafor(AMD3100)
• 1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylMethyl)phenyl]Methyl}-1,4,8,11-tetraazacyclotetradecane
• MOZOBIL PLERIXAFOR
• plerixafor, AMD 3100, AMD-3100, AMD3100, JLK 169, Mozobil, 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylMethyl)phenyl] Methyl]-1,4,8,11-tetrazacyclotetradecane
• PLERIXAFOR
• Plerixafor/JM3100/AMD3100
• 1,4-bis((1,4,8,11-tetraazacyclotetradecan-1-yl)Methyl)benzene
• 1,4-Bis((1,4,8,11-tetraazacyclotetradecan-1-yl)Methyl)benzene,95+%
• AMD3100 (Plerixafor)
• AMD310
• CS-269
• 1;4;8;11-TETRAAZACYCLOTETRADECANE; 1;1'-[1;4-PHENYLENEBIS(METHYLENE)]BIS;AMD 3100;AMD-3100
• 11-Tetraazacyclotetradecane
• 4-phenylenebis(methylene)]bis
• AMD-3329
• PLERIXAFOR USP/EP/BP
• Plerixafo
• Plerixafor (125 mg)
• プレリキサフォル
• プレリキサホル
• プレリキサホル (JAN)
• プレリキサフォ
• 1,1′-(1,4-フェニレンビスメチレン)ビス(1,5,8,12-テトラアザシクロテトラデカン)
• 1,4-ビス(1,4,8,11-テトラアザシクロテトラデカン-1-イルメチル)ベンゼン
• 1,1′-(1,4-キシリレン)ビス(1,4,8,11-テトラアザシクロテトラデカン)
• 1-({4-[(1,4,8,11-テトラアザシクロテトラデカン-1-イル)メチル]フェニル}メチル)-1,4,8,11-テトラアザシクロテトラデカン
• 1,1′-(p-フェニレンビスメチレン)ビス(1,4,8,11-テトラアザシクロテトラデカン)
• 11,11′-(p-フェニレンビスメチレン)ビス(1,4,8,11-テトラアザシクロテトラデカン)
• 4,4′-(1,4-キシリレン)ビス(1,4,8,11-テトラアザシクロテトラデカン)
• プレリキサフォー
• 1,1′-(p-キシリレン)ビス(1,4,8,11-テトラアザシクロテトラデカン)
• 1,1′-[1,4-フェニレンビス(メチレン)]ビス(1,4,8,11-テトラアザシクロテトラデカン)
• 1,1′-(1,4-フェニレンビスメチレン)ビス(1,4,8,11-テトラアザシクロテトラデカン)
• 1,1′-p-キシリレンビス(1,4,8,11-テトラアザシクロテトラデカン)
• 7,7′-(1,4-フェニレンビスメチレン)ビス[4,7,10,17-テトラアザビシクロ[11.3.1]ヘプタデカ-1(16),13(17),14-トリエン]
• 7-{[4-({4,7,10,17-テトラアザビシクロ[11.3.1]ヘプタデカ-1(17),13,15-トリエン-7-イル}メチル)フェニル]メチル}-4,7,10,17-テトラアザビシクロ[11.3.1]ヘプタデカ-1(17),13,15-トリエン
• モゾビル